Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to PET ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Diagnostic accuracy of parkinsonism syndromes by general neurologists.Parkinsonism Relat Disord+. 2014; 20: 840-844
- The diagnosis of Parkinson's disease.Lancet Neurol. 2006; 5: 75-86
- The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service.Brain. 2002; 125: 861-870
Parkinson, J. An essay on the shaking palsy. London, Sherwood, Neely and Jones, 1817. Hovever, this is pretty difficult to locate in most library resources. The monograph was re-printed verbatum on pages 145-218 of the book: Critchley M, James Parkinson, London. MacMillan & Co, LTD, 1955.
- Past, present, and future of Parkinson's disease: a special essay on the 200th Anniversary of the Shaking Palsy. [Review].Mov Disord. 2017; 32: 1264-1310
- Diagnostic criteria for Parkinson’s disease.Arch Neurol. 1999; 56: 33-39
- Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria.Lancet Neurol. 2009; 8: 1150-1157
- Staging of brain pathology related to sporadic Parkinson’s disease.Neurobiol Aging. 2003; 24: 197-211
- α-Synuclein in Lewy bodies.Nature. 1997; 388: 839-840
- Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction.Acta Neuropathol. 2009; 117: 613-634
- The Parkinson's complex: parkinsonism is just the tip of the iceberg.Ann Neurol. 2006; 59: 591-596
- The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations.Brain. 2004; 127: 2657-2671
- Second consensus statement on the diagnosis of multiple system atrophy.Neurology. 2008; 71: 670-676
- Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy. [Review].J Neurol Neurosurg Psychiatr. 2018; 89: 175-184
- Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy–Drager syndrome).J Neurol Sci. 1989; 94: 79-100
- The distribution and dynamic density of oligodendroglial cytoplasmic inclusions (GCIs) in multiple system atrophy: a correlation between the density of GCIs and the degree of involvement of striatonigral and olivopontocerebellar systems.Acta Neuropathol. 1997; 93: 585-591
- Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy.Neurosci Lett. 1998; 249: 180-182
- Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies.Neurosci Lett. 1998; 251: 205-208
- Multiple system atrophy: a sporadic synucleinopathy.Brain Pathol. 1999; 9: 721-732
- Widespread alterations of alpha-synuclein in multiple system atrophy.Am J Pathol. 1999; 155: 1241-1251
- Neuropathology underlying clinical variability in patients with synucleinopathies.Acta Neuropathol. 2011; 122: 187-204
- Expanding the spectrum of neuronal pathology in multiple system atrophy.Brain. 2015; 138: 2293-2309
- Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.Neurology. 1996; 47: 1-9
- Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. [Review].Lancet Neurol. 2017; 16: 552-563
- Neuropathology of variants of progressive supranuclear palsy. [Review].Curr Opin Neurol. 2010; 23: 394-400
- Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). [Review].J Mol Neurosci. 2011; 45: 384-389
- Parkinson's disease and parkinsonism: neuropathology.Cold Spring Harb Perspect Med. 2012; 2: a009258
- Cognitive impairment in progressive supranuclear palsy is associated with tau burden.Mov Disord. 2017; 32: 1772-1779
- Diagnostic criteria for corticobasal syndrome: a comparative study.J Neurol Neurosurg Psychiatr. 2012; 83: 405-410
- Validation of the new consensus criteria for the diagnosis of corticobasal degeneration.J Neurol Neurosurg Psychiatr. 2014; 85: 925-929
- Astrocytic plaques and tufts of abnormal fibers do not coexist in corticobasal degeneration and progressive supranuclear palsy.Acta Neuropathol. 1998; 96: 401-408
- Corticobasal degeneration: a pathologically distinct 4R tauopathy.Nat Rev Neurol. 2011; 7: 263-272
- FDG PET in the differential diagnosis of parkinsonian disorders.Neuroimage. 2005; 26: 912-921
- Recent advancement and clinical implications of 18FDG-PET in Parkinson's disease, atypical parkinsonisms, and other movement disorders. [Review].Curr Neurol Neurosci Rep. 2019; 19: 06
- Functional imaging with positron emission tomography in multiple system atrophy.J Neural Transm (Vienna). 2005; 112: 1647-1655
- FDG-PET patterns associated with underlying pathology in corticobasal syndrome.Neurology. 2019; 92: e1121-e1135
- Validation of parkinsonian disease-related metabolic brain patterns.Mov Disord. 2013; 28: 547-551
- Automated differential diagnosis of early parkinsonism using metabolic brain networks: a validation study.J Nucl Med. 2016; 57: 60-66
- Evaluation of an optimized [18 F]fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders.Eur J Neurol. 2017; 24: 687-e26
- The utility of FDG-PET in the differential diagnosis of Parkinsonism.Neurol Res. 2017; 39: 675-684
- PET imaging in movement disorders. [Review].Semin Nucl Med. 2018; 48: 513-524
- Molecular imaging of dopamine transporters. [Review].Ageing Res Rev. 2016; 30: 114-121
- Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease.Mov Disord. 2019; 34: 1505-1515
- 11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: a longitudinal study.Mov Disord. 2018; 33: 117-127
- Nigrostriatal dopamine transporter availability in early Parkinson's disease.Mov Disord. 2018; 33: 592-599
- Nigrostriatal dopamine terminal imaging with dopamine transporter SPECT: an update. [Review].J Nucl Med. 2013; 54: 1331-1338
- 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.Neurol Sci. 2003; 24: 149-150
- FP-CIT and IBZM-SPECT in corticobasal syndrome: results from a clinical follow-up study.Neurodegener Dis. 2016; 16: 342-347
- Different loss of dopamine transporter according to subtype of multiple system atrophy.Eur J Nucl Med Mol Imaging. 2016; 43: 517-525
- Patterns of dopamine transporter imaging in subtypes of multiple system atrophy.Acta Neurol Scand. 2018; 138: 170-176
- D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia.Neurology. 2016; 86: 224-230
- Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review.J Cereb Blood Flow Metab. 2000; 20: 423-451
- Central pharmacokinetics of levodopa: lessons from imaging studies. [Review].Mov Disord. 2015; 30: 73-79
- Neurobiology of placebo effect in Parkinson's disease: what we have learned and where we are going. [Review].Mov Disord. 2018; 33: 1213-1227
- Spared caudal brainstem SERT binding in early Parkinson's disease.J Cereb Blood Flow Metab. 2008; 28: 441-444
- Serotonin-to-dopamine transporter ratios in Parkinson disease: relevance for dyskinesias.Neurology. 2016; 86: 1152-1158
- Serotonin transporter in Parkinson's disease: a meta-analysis of positron emission tomography studies. [Review].Ann Neurol. 2017; 81: 171-180
- Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET.NeuroImage Clin. 2018; 19: 652-660
- The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease.Brain. 2016; 139: 2486-2502
- Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study.Brain. 2018; 141: 496-504
- Noradrenergic deficits in Parkinson disease imaged with 11C-MeNER.J Nucl Med. 2018; 59: 659-664
- Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients.Mov Disord. 2018; 33: 1006-1010
- 2-Year natural decline of cardiac sympathetic innervation in idiopathic Parkinson disease studied with 11C-Hydroxyephedrine PET.J Nucl Med. 2017; 58: 326-331
- Molecular imaging of the cholinergic system in Parkinson's disease.Int Rev Neurobiol. 2018; 141: 211-250
- In vivo imaging of human cholinergic nerve terminals with (-)-5-18F-fluoroethoxybenzovesamicol: biodistribution, dosimetry, and tracer kinetic analyses.J Nucl Med. 2014; 55: 396-404
- Regional vesicular acetylcholine transporter distribution in human brain: a [18 F]fluoroethoxybenzovesamicol positron emission tomography study.J Comp Neurol. 2018; 526: 2884-2897
- Cholinergic system changes of falls and freezing of gait in Parkinson's disease.Ann Neurol. 2019; 85: 538-549
- Nicotine and nicotinic receptor drugs: potential for Parkinson's disease and drug-induced movement disorders.Int Rev Neurobiol. 2015; 124: 247-271
- Cholinergic activity and levodopa-induced dyskinesia: a multitracer molecular imaging study.Ann Clin Transl Neurol. 2017; 4: 632-639
- Decreased intestinal acetylcholinesterase in early Parkinson disease: an 11C-donepezil PET study.Neurology. 2017; 88: 775-781
- In vivo positron emission tomography imaging of decreased parasympathetic innervation in the gut of vagotomized patients.Neurogastroenterol Motil. 2020; 32: e13759
- The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.Lancet Neurol. 2018; 17: 309-316
- Brain amyloid imaging.J Nucl Med. 2011; 52: 1733-1740
- Small-molecule PET tracers for imaging proteinopathies. [Review].Semin Nucl Med. 2017; 47: 553-575
- Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.JAMA. 2015; 313: 1924-1938
- Biomarker modeling of Alzheimer's disease.Neuron. 2013; 80: 1347-1358
- Amyloid deposition in Parkinson’s disease and cognitive impairment: a systematic review.Mov Disord. 2015; 30: 928-935
- Extremely low prevalence of amyloid positron emission tomography positivity in Parkinson's disease without dementia.Eur Neurol. 2017; 77: 231-237
- Abeta-amyloid deposition in patients with Parkinson disease at risk for development of dementia.Neurology. 2012; 79: 1161-1167
- Striatal and cortical beta-amyloidopathy and cognition in Parkinson's disease.Mov Disord. 2016; 31: 111-117
- Regional brain amyloid-beta accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia.PLoS ONE. 2017; 12 ([Electronic Resource]): e0177924
- Brain amyloid contribution to cognitive dysfunction in early-stage Parkinson's disease: the PPMI dataset.J Alzheimers Dis. 2018; 66: 229-237
- Network patterns of beta-amyloid deposition in Parkinson's disease.Mol Neurobiol. 2019; 56: 7731-7740
- Apathy rating scores and beta-amyloidopathy in patients with Parkinson disease at risk for cognitive decline.Neurology. 2020; 94: e376-e383
- Serotonin, beta-amyloid, and cognition in Parkinson disease.Ann Neurol. 2018; 83: 994-1002
- Tau protein isoforms, phosphorylation and role in neurodegenerative disorders.Brain Res Brain Res Rev. 2000; 33: 95-130
- The challenges of tau imaging.Future Neurol. 2012; 7: 409-421
- Tau imaging: early progress and future directions.Lancet Neurol. 2015; 14: 114-124
- 18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: a multicenter study.Ann Neurol. 2017; 82: 622-634
- [18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy.Mov Disord. 2017; 32: 124-133
- Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy.Mov Disord. 2017; 32: 108-114
- In vivo retention of 18F-AV-1451 in corticobasal syndrome.Neurology. 2017; 89: 845-853
- Positron emission tomography imaging of tau pathology in progressive supranuclear palsy.J Cereb Blood Flow Metab. 2017; 37: 3150-3160
- 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.Brain. 2017; 140: 781-791
- Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies.Ann Neurol. 2017; 81: 117-128
- Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue.Ann Neurol. 2015; 78: 787-800
- An autoradiographic evaluation of AV-1451 Tau PET in dementia.Acta Neuropathol Commun. 2016; 4: 58
- Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias.Alzheimers Demen. 2016; 12: 1116-1124
- The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases.Mov Disord. 2018; 33: 273-281
- In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.Brain. 2016; 139: 2039-2049
- [18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP.Brain Struct Funct. 2018; 223: 589-595
- Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.Neuron. 2013; 79: 1094-1108
- PBB3 imaging in Parkinsonian disorders: evidence for binding to tau and other proteins.Mov Disord. 2017; 32: 1016-1024
- In vivo binding of a tau imaging probe, [11 C]PBB3, in patients with progressive supranuclear palsy.Mov Disord. 2019; 34: 744-754
- Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.Brain. 2017; 140: 764-780
- Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to alpha-synuclein pathology.Mov Disord. 2017; 32: 884-892
- Alpha synuclein fibrils contain multiple binding sites for small molecules.ACS Chem Neurosci. 2018; 9: 2521-2527
- In silico, in vitro, and in vivo evaluation of new candidates for alpha-synuclein PET imaging.Mol Pharm. 2018; 15: 3153-3166
- The binding of BF-227-like benzoxazoles to human α-synuclein and amyloid β peptide fibrils.Mol Imaging. 2018; 17 (1536012118796297)
Article info
Publication history
Published online: February 12, 2021
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
